Modular Medical, Inc.: Modular Medical Announces Contract with National U.S. Pharmacy Benefit Manager, Expanding Access to Pivot Tubeless Patch Pump

Modular Medical, Inc. (NASDAQ:MODD) announced a contract with a national U.S. pharmacy benefit manager (PBM), expanding access to its Pivot tubeless patch pump for diabetes patients. The company believes this partnership will broaden patient access and validate its insulin delivery system. Modular Medical aims to simplify diabetes management with its innovative medical device.

Original reporting
Published Sep 4, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MODD
Bullish
medium confidence
Mentioned
$MODD
Relevance
5/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$MODDBullishLow
01

Why it matters

The PBM contract could improve formulary placement and patient access, supporting revenue growth, but the lack of disclosed financial terms tempers expectations.

02

Market read

A new distribution agreement for a diabetes device may boost Modular Medical's outlook, though impact size is uncertain.

03

What to watch

Potential reimbursement negotiations, competitive response from established pump makers, and execution risk of scaling manufacturing.

Relevance 5/10Novelty 6/10Timing: today

Background

Modular Medical is a commercial‑stage medical‑device company focused on insulin delivery technologies. The Pivot tubeless patch pump is its flagship product.

Company-level read

Ticker impact

$MODDBullishMedium confidence
Context

Modular Medical announced a contract with a national U.S. pharmacy benefit manager to make its Pivot tubeless patch pump available through the PBM.

Expected impact

Modular Medical may see modest upside pressure as market participants price in broader patient access.

Evidence & confidence

The announcement is a fresh commercial milestone, but no financial terms were disclosed, limiting the magnitude of the expected impact.

Market effects

The deal highlights growing importance of PBM partnerships for diabetes device manufacturers.

U.S. diabetes device market may see incremental demand as insurers adopt the Pivot pump.

Limited; the news is specific to the U.S. market and does not affect global peers significantly.

Counterpoint

Without disclosed pricing or volume, the contract may not materially move the stock and could be over‑hyped.

Key entities

  • Modular Medical, Inc.

    Issuer of the Pivot tubeless patch pump.

  • National U.S. Pharmacy Benefit Manager

    Unnamed large PBM that will carry the Pivot pump.

Related articles

$MODDHigh

Modular Medical stock rises after securing PBM contract

Modular Medical Inc (MODD) shares rose 2.3% after securing a contract with a national U.S. pharmacy benefit manager, making its Pivot insulin delivery system available through the PBM. The company aims to broaden patient access to its Pivot tubeless patch pump, a wearable insulin delivery platform for diabetes management.

$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

$LLYMed

Lilly’s retatrutide shows greater efficacy than Ozempic in trial

Eli Lilly (NYSE:LLY) reported that retatrutide outperformed Ozempic in a Phase 3 trial for type 2 diabetes. Retatrutide reduced A1C levels by 2.2% vs. Ozempic's 1.8% and led to 44-47 lbs weight loss vs. Ozempic's 21 lbs. Both doses met primary and secondary endpoints. Common side effects included diarrhea and nausea. Retatrutide is not yet FDA-approved.

$JMed

Jacobs wins $1B San Francisco wastewater treatment contract

Jacobs (J) won a $1B contract for the Southeast Treatment Plant Nutrient Reduction Project in San Francisco. The project, a joint venture with PCL Construction, will upgrade the city's largest wastewater treatment plant. Jacobs expects to meet environmental requirements and invest in local community initiatives. The company reported $12B in annual revenue and 47,000 employees.

$JMed

Jacobs (J) Selected for SFPUC’s $1B Wastewater Upgrade

Jacobs, in a joint venture with PCL Construction, was chosen by the San Francisco Public Utilities Commission for a $1B wastewater upgrade project. This selection supports Jacobs' focus on water and design-build programs, potentially boosting its regulated infrastructure backlog.